![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MS4A2 |
Gene summary for MS4A2 |
![]() |
Gene information | Species | Human | Gene symbol | MS4A2 | Gene ID | 2206 |
Gene name | membrane spanning 4-domains A2 | |
Gene Alias | APY | |
Cytomap | 11q12.1 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q01362 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2206 | MS4A2 | CA_HPV_1 | Human | Cervix | CC | 8.58e-19 | -7.09e-01 | 0.0264 |
2206 | MS4A2 | CA_HPV_3 | Human | Cervix | CC | 8.28e-05 | -4.49e-01 | 0.0414 |
2206 | MS4A2 | N_HPV_2 | Human | Cervix | N_HPV | 5.12e-10 | -6.44e-01 | -0.0131 |
2206 | MS4A2 | CCI_1 | Human | Cervix | CC | 1.46e-05 | -9.18e-01 | 0.528 |
2206 | MS4A2 | CCI_2 | Human | Cervix | CC | 5.47e-05 | -9.18e-01 | 0.5249 |
2206 | MS4A2 | CCI_3 | Human | Cervix | CC | 7.16e-08 | -9.18e-01 | 0.516 |
2206 | MS4A2 | CCII_1 | Human | Cervix | CC | 2.06e-11 | -9.18e-01 | 0.3249 |
2206 | MS4A2 | Tumor | Human | Cervix | CC | 5.21e-31 | -9.18e-01 | 0.1241 |
2206 | MS4A2 | sample1 | Human | Cervix | CC | 2.49e-09 | -9.18e-01 | 0.0959 |
2206 | MS4A2 | sample3 | Human | Cervix | CC | 4.93e-29 | -9.18e-01 | 0.1387 |
2206 | MS4A2 | H2 | Human | Cervix | HSIL_HPV | 2.93e-28 | -8.98e-01 | 0.0632 |
2206 | MS4A2 | L1 | Human | Cervix | CC | 1.21e-12 | -9.18e-01 | 0.0802 |
2206 | MS4A2 | T1 | Human | Cervix | CC | 1.18e-21 | -9.18e-01 | 0.0918 |
2206 | MS4A2 | T2 | Human | Cervix | CC | 1.22e-04 | -9.18e-01 | 0.0709 |
2206 | MS4A2 | T3 | Human | Cervix | CC | 1.21e-28 | -9.18e-01 | 0.1389 |
2206 | MS4A2 | HCC1 | Human | Liver | HCC | 1.73e-10 | 1.17e+00 | 0.5336 |
2206 | MS4A2 | HCC2 | Human | Liver | HCC | 1.58e-22 | 1.31e+00 | 0.5341 |
2206 | MS4A2 | HCC5 | Human | Liver | HCC | 8.95e-17 | 1.11e+00 | 0.4932 |
2206 | MS4A2 | EOLP-1 | Human | Oral cavity | EOLP | 1.02e-07 | 5.10e-01 | -0.0202 |
2206 | MS4A2 | EOLP-2 | Human | Oral cavity | EOLP | 7.24e-29 | 8.63e-01 | -0.0203 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00380933 | Cervix | CC | Fc receptor signaling pathway | 19/2311 | 50/18723 | 3.42e-06 | 9.17e-05 | 19 |
GO:0038095 | Cervix | CC | Fc-epsilon receptor signaling pathway | 11/2311 | 24/18723 | 5.28e-05 | 7.88e-04 | 11 |
GO:0002768 | Cervix | CC | immune response-regulating cell surface receptor signaling pathway | 59/2311 | 315/18723 | 6.64e-04 | 6.11e-03 | 59 |
GO:000276411 | Cervix | HSIL_HPV | immune response-regulating signaling pathway | 46/737 | 468/18723 | 1.17e-08 | 1.30e-06 | 46 |
GO:00027681 | Cervix | HSIL_HPV | immune response-regulating cell surface receptor signaling pathway | 32/737 | 315/18723 | 9.80e-07 | 4.68e-05 | 32 |
GO:003809311 | Cervix | HSIL_HPV | Fc receptor signaling pathway | 8/737 | 50/18723 | 6.88e-04 | 9.21e-03 | 8 |
GO:000276421 | Cervix | N_HPV | immune response-regulating signaling pathway | 36/534 | 468/18723 | 7.52e-08 | 7.81e-06 | 36 |
GO:00027682 | Cervix | N_HPV | immune response-regulating cell surface receptor signaling pathway | 22/534 | 315/18723 | 1.11e-04 | 2.18e-03 | 22 |
GO:000276413 | Oral cavity | EOLP | immune response-regulating signaling pathway | 108/2218 | 468/18723 | 4.04e-12 | 7.34e-10 | 108 |
GO:003809313 | Oral cavity | EOLP | Fc receptor signaling pathway | 19/2218 | 50/18723 | 1.84e-06 | 4.26e-05 | 19 |
GO:00027683 | Oral cavity | EOLP | immune response-regulating cell surface receptor signaling pathway | 66/2218 | 315/18723 | 2.44e-06 | 5.45e-05 | 66 |
GO:00380951 | Oral cavity | EOLP | Fc-epsilon receptor signaling pathway | 10/2218 | 24/18723 | 2.17e-04 | 2.16e-03 | 10 |
GO:000276422 | Oral cavity | NEOLP | immune response-regulating signaling pathway | 74/2005 | 468/18723 | 3.90e-04 | 3.63e-03 | 74 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa04664 | Cervix | CC | Fc epsilon RI signaling pathway | 22/1267 | 68/8465 | 2.35e-04 | 1.31e-03 | 7.77e-04 | 22 |
hsa053107 | Cervix | CC | Asthma | 11/1267 | 31/8465 | 3.82e-03 | 1.36e-02 | 8.03e-03 | 11 |
hsa0407113 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa046641 | Cervix | CC | Fc epsilon RI signaling pathway | 22/1267 | 68/8465 | 2.35e-04 | 1.31e-03 | 7.77e-04 | 22 |
hsa0531012 | Cervix | CC | Asthma | 11/1267 | 31/8465 | 3.82e-03 | 1.36e-02 | 8.03e-03 | 11 |
hsa0407141 | Oral cavity | EOLP | Sphingolipid signaling pathway | 44/1218 | 121/8465 | 1.19e-09 | 3.51e-08 | 2.07e-08 | 44 |
hsa046642 | Oral cavity | EOLP | Fc epsilon RI signaling pathway | 23/1218 | 68/8465 | 4.23e-05 | 2.01e-04 | 1.19e-04 | 23 |
hsa040722 | Oral cavity | EOLP | Phospholipase D signaling pathway | 31/1218 | 148/8465 | 1.82e-02 | 4.67e-02 | 2.76e-02 | 31 |
hsa0407151 | Oral cavity | EOLP | Sphingolipid signaling pathway | 44/1218 | 121/8465 | 1.19e-09 | 3.51e-08 | 2.07e-08 | 44 |
hsa0466411 | Oral cavity | EOLP | Fc epsilon RI signaling pathway | 23/1218 | 68/8465 | 4.23e-05 | 2.01e-04 | 1.19e-04 | 23 |
hsa0407211 | Oral cavity | EOLP | Phospholipase D signaling pathway | 31/1218 | 148/8465 | 1.82e-02 | 4.67e-02 | 2.76e-02 | 31 |
hsa0407161 | Oral cavity | NEOLP | Sphingolipid signaling pathway | 36/1112 | 121/8465 | 1.11e-06 | 1.21e-05 | 7.64e-06 | 36 |
hsa0407171 | Oral cavity | NEOLP | Sphingolipid signaling pathway | 36/1112 | 121/8465 | 1.11e-06 | 1.21e-05 | 7.64e-06 | 36 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MS4A2 | SNV | Missense_Mutation | novel | c.110G>T | p.Arg37Ile | p.R37I | Q01362 | protein_coding | tolerated(0.19) | benign(0.001) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
MS4A2 | SNV | Missense_Mutation | novel | c.34N>A | p.Ala12Thr | p.A12T | Q01362 | protein_coding | tolerated(0.09) | benign(0.014) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
MS4A2 | SNV | Missense_Mutation | c.10N>A | p.Glu4Lys | p.E4K | Q01362 | protein_coding | deleterious(0.02) | benign(0.115) | TCGA-B5-A11R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | |
MS4A2 | SNV | Missense_Mutation | novel | c.394N>A | p.Gly132Arg | p.G132R | Q01362 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MS4A2 | insertion | Frame_Shift_Ins | novel | c.292_293insT | p.Ala98ValfsTer22 | p.A98Vfs*22 | Q01362 | protein_coding | TCGA-D1-A102-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
MS4A2 | insertion | Nonsense_Mutation | novel | c.293_294insTTTATG | p.Ala98_Gly99insLeuTer | p.A98_G99insL* | Q01362 | protein_coding | TCGA-D1-A102-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
MS4A2 | SNV | Missense_Mutation | c.291A>T | p.Lys97Asn | p.K97N | Q01362 | protein_coding | tolerated(0.1) | benign(0.078) | TCGA-ED-A459-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Ancillary | alvesin | CR | |
MS4A2 | SNV | Missense_Mutation | c.288N>G | p.Phe96Leu | p.F96L | Q01362 | protein_coding | deleterious(0.01) | possibly_damaging(0.732) | TCGA-05-4418-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
MS4A2 | SNV | Missense_Mutation | novel | c.134N>A | p.Pro45Gln | p.P45Q | Q01362 | protein_coding | tolerated(0.12) | benign(0.092) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD |
MS4A2 | SNV | Missense_Mutation | rs750693474 | c.106N>A | p.Gly36Ser | p.G36S | Q01362 | protein_coding | tolerated(0.73) | benign(0.011) | TCGA-64-5775-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2206 | MS4A2 | EXTERNAL SIDE OF PLASMA MEMBRANE | OMALIZUMAB | OMALIZUMAB | ||
2206 | MS4A2 | EXTERNAL SIDE OF PLASMA MEMBRANE | R112 |
Page: 1 |